Wockhardt Limited 's Board of Directors, at its meeting held on May 4, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors, M/s. M S K C & Associates LLP, issued an unmodified audit opinion on both the standalone and consolidated financial results. The board meeting commenced at 11:00 a.m. and concluded at 3:10 p.m.

Standalone Financial Performance

Wockhardt reported a strong turnaround in its standalone financials for FY26. The company swung to a net profit of ₹317 Crore for the year ended March 31, 2026, compared to a net loss of ₹12 Crore in the prior year. Revenue from operations grew to ₹1,739 Crore from ₹1,402 Crore. The following table summarises the key standalone financial metrics:

*not annualised; face value of ₹5/- each

On the standalone balance sheet, total assets stood at ₹5,935 Crore as at March 31, 2026, compared to ₹5,408 Crore in the prior year. Total equity increased to ₹3,084 Crore from ₹2,763 Crore, with other equity rising to ₹3,003 Crore from ₹2,682 Crore. Standalone cash and cash equivalents at the end of the year stood at ₹76 Crore, up from ₹35 Crore at the beginning of the year, with net cash inflow from operating activities of ₹241 Crore for FY26 against a net outflow of ₹14 Crore in FY25.

Consolidated Financial Performance

On a consolidated basis, Wockhardt's group revenue from operations grew to ₹3,373 Crore in FY26 from ₹3,012 Crore in FY25. Total consolidated income for FY26 stood at ₹3,484 Crore compared to ₹3,074 Crore in the prior year. The group reported a net profit after tax of ₹199 Crore for FY26, reversing a net loss of ₹57 Crore in FY25. Net profit attributable to equity shareholders of the company was ₹213 Crore for FY26, compared to a loss of ₹47 Crore in FY25.

*not annualised; face value of ₹5/- each

Consolidated total assets as at March 31, 2026 stood at ₹8,615 Crore against ₹8,135 Crore in the prior year. Total consolidated equity increased to ₹5,281 Crore from ₹4,657 Crore. Consolidated cash and cash equivalents at the end of the year were ₹217 Crore, up from ₹112 Crore, with net cash inflow from operating activities of ₹390 Crore for FY26 against a net outflow of ₹22 Crore in FY25.

Q4 EBITDA Performance

Wockhardt's operational profitability showed a marked improvement in Q4, with consolidated EBITDA and margin expanding significantly on a year-on-year basis. The table below highlights the key Q4 EBITDA metrics:

Exceptional Items

Several exceptional items impacted the financial results for FY26. The key items are summarised below:

• Settlement with Dr. Reddy's Laboratories: Wockhardt had previously concluded a Business Transfer Agreement ("BTA") with Dr. Reddy's Laboratories Limited on February 12, 2020, for the transfer of a portion of its Domestic Branded Division, with total consideration of ₹1,850 Crores, of which ₹300 Crores was designated as a "Holdback Amount." The company entered into a full and final settlement of all claims and disputes under the BTA effective March 31, 2026, recognising a net gain of ₹35 Crore under Exceptional Items for the quarter ended March 31, 2026.
• Deconsolidation of US Subsidiaries (Consolidated): The group decided to exit the US generic pharmaceutical business and filed for voluntary liquidation on July 11, 2025 under Chapter 7 of the US Bankruptcy Code for its US step-down subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC. The group recognised an initial charge of ₹97 Crores under Exceptional Items for the quarter ended September 30, 2025. During the quarter ended March 31, 2026, the group executed a settlement agreement with the Chapter 7 trustee, resulting in a net additional charge of ₹13 Crores. The total consolidated exceptional items for FY26 amount to a net charge of ₹85 Crores.
• Impact of New Labour Codes: Effective November 21, 2025, the Government of India consolidated multiple existing labour legislations into four Labour Codes. The company assessed and accounted for the incremental impact based on actuarial valuation, amounting to ₹10 Crores as an Exceptional Item.

Fund Raising Proposal and Other Developments

The Board also approved an enabling proposal for raising funds through the issue of equity shares, securities convertible into equity shares, non-convertible securities, or any combination thereof, through public or private offerings, Qualified Institutions Placement, preferential allotment, or any other permissible method, in one or more tranches. This proposal is subject to the consent of shareholders at the ensuing Annual General Meeting and such other approvals and compliances as may be required. The consolidated results encompass Wockhardt Limited and 31 subsidiaries, with the group operating exclusively in the pharmaceutical business segment.

Source: None/Company/INE049B01025/eecea18099a9419c.pdf

Wockhardt Limited's Board of Directors, at its meeting held on May 4, 2026, identified and designated three individuals as Senior Management Personnel (SMP) of the Company, in compliance with Regulation 30 (read with Part A of Schedule III) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The newly designated SMPs are Ms. Annapurna Das, Mr. Om Narayan, and Mr. Sunil Soni, each taking on senior leadership roles across the company's commercial and biotechnology functions.

Senior Management Designations at a Glance

The following table summarises the key details of the three newly designated Senior Management Personnel:

Profile: Ms. Annapurna Das — President, India Business & Emerging Markets (NCE)

Ms. Annapurna Das, aged 52 years, holds a B.Tech (Chemical Engineering) degree from BIT Sindri and an M.B.A. (Marketing) from Madurai Kamraj University. She brings over 26 years of experience across general management, strategy, and commercial operations in India and Asia. Prior to this designation, she served as Vice President and General Manager at Takeda India, where she led the India and Sri Lanka business for a super-specialty portfolio spanning oncology, biologics, gastroenterology, and rare diseases. She also served as Managing Director and Area Head for India and Southeast Asia at Miltenyi Biotec, where she established and scaled cell and gene therapy operations in the region. Additionally, she held senior leadership roles at Sanofi, including non-independent Board member and Head of Asia (Vaccines), as well as strategy and business development roles at MSD, GSK, Pfizer, and Organon.

Profile: Mr. Om Narayan — Senior Vice President, Biotech Research Centre

Mr. Om Narayan, aged 52 years, holds a Master's degree in Biotechnology from Goa University (1995). He brings nearly three decades of diverse experience across R&D, manufacturing, biosimilars, and vaccines. Over the course of his career, he has held senior leadership roles at organisations including Piramal Pharmaceuticals, Kashiv BioSciences, Mylan (Viatris), Biological E Limited, Intas Biopharma, Avesthagen, Serum Institute of India, and Wockhardt Research Center. His contributions span multiple global biosimilar and vaccine approvals as well as facility setups.

Profile: Mr. Sunil Soni — Senior Vice President, Biotechnology

Mr. Sunil Soni, aged 54 years, holds a Master's degree in Bio-Chemical Engineering & Biotechnology from IIT Delhi (1993). He brings nearly three decades of rich experience in projects, manufacturing operations, process development, scale-up, and process improvement initiatives across API and biotech industries. He has held senior leadership roles at Biological E., Serum Institute of India, Concord Biotech Ltd, Gujarat Themis Biosyn Ltd, Wockhardt Ltd., and Lupin Chemicals Ltd, contributing across process operations, equipment design operations, manufacturing operations, production planning & inventory control, and projects & commissioning.

Regulatory Disclosure

The designations have been disclosed in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026. The information has also been made available on the company's official website at https://www.wockhardt.com . The disclosure was signed by Ms. Rashmi Mamtura, Company Secretary of Wockhardt Limited.